The nanocomplex materials to be provided by PeptiMed will harbor motifs that bind to cell adhesion molecules on the surface of cancer cells and deliver an siRNA payload that silences the oncogene, EVI1. Initially, the NCL will assess the physical and chemical properties of the nanocomplexes followed by their purity and sterility in cell culture models. A second phase of testing for various modes of toxicity may be performed in animal models.
“We are profoundly pleased to work with the NCL to further our understanding of PeptiMed nanomaterials,” stated
PeptiMed co-founder Dr.
The mission of PeptiMed is to discover and provide nucleotide-based therapies and delivery systems for nucleotide-based drugs with unprecedented potency in ameliorating late-stage cancer while avoiding debilitating side effects, thereby improving prognosis and quality of life for each patient. PeptiMed has patented the hELPTM nanoparticle delivery system for nucleotides. PeptiMed plans to begin first-in-human studies to determine maximum tolerated and efficacious doses of the EVIRNATM/hELPTM nanocomplex by the end of FY2015.
This press release contains positive forward-looking statements concerning the therapeutic value of PeptiMed’s EVIRNATM/hELPTM nanocomplex. For further information please view the website www.peptimed.com or contactDr.
Chief Business Officer
Most Popular Stories
- Criminal Investigation Opened Into James Foley's Death
- Investors Betting on ECB Stimulus Measures
- Jennifer Lopez Would Marry Again
- Hackers Get Homeland Security Employee Records
- Apple Stock Bounces Back Big Time
- 'Mythbusters' Build Team Gets the Boot
- Mo'Ne Davis a Big Winner Despite Loss
- Advocacy Group Calls for Chrysler Probe
- DHS Warns Retailers About Malware in Cash Registers
- Florida Judge Rules in Favor of GOP Voter Map